← FDA DRUG APPROVALS

FDA ANDA · ANDA079108

DEXMETHYLPHENIDATE HYDROCHLORIDE

Sponsor: IMPAX LABS INC

APPLICATION
ANDA079108
TYPE
ANDA
ORIGINAL APPROVAL
2013-11-21
LATEST ACTION
2024-12-17
ROUTE
ORAL
DOSAGE FORM
CAPSULE, EXTENDED RELEASE
MARKETING STATUS
Prescription

Products

DEXMETHYLPHENIDATE HYDROCHLORIDEPrescription
DEXMETHYLPHENIDATE HYDROCHLORIDE 20MG · CAPSULE, EXTENDED RELEASE · ORAL
DEXMETHYLPHENIDATE HYDROCHLORIDEPrescription
DEXMETHYLPHENIDATE HYDROCHLORIDE 10MG · CAPSULE, EXTENDED RELEASE · ORAL
DEXMETHYLPHENIDATE HYDROCHLORIDEPrescription
DEXMETHYLPHENIDATE HYDROCHLORIDE 30MG · CAPSULE, EXTENDED RELEASE · ORAL
DEXMETHYLPHENIDATE HYDROCHLORIDEPrescription
DEXMETHYLPHENIDATE HYDROCHLORIDE 15MG · CAPSULE, EXTENDED RELEASE · ORAL
DEXMETHYLPHENIDATE HYDROCHLORIDEPrescription
DEXMETHYLPHENIDATE HYDROCHLORIDE 5MG · CAPSULE, EXTENDED RELEASE · ORAL

Approval history

2024-12-17Labeling · Supplement 7 · standardAP
2024-12-17Labeling · Supplement 11 · standardAP
2024-12-17Labeling · Supplement 16 · standardAP
2024-12-17Labeling · Supplement 10 · standardAP
2019-11-29Labeling · Supplement 6 · standardAP
2019-11-29Labeling · Supplement 4 · standardAP
2015-12-28Labeling · Supplement 3 · standardAP
2015-12-21OriginalAP
2015-08-05OriginalAP
2014-05-19OriginalAP
2014-01-22Labeling · Supplement 1 · standardAP
2013-11-21Original — Letter ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →